

Claim 8 claims a composition according to claim 1 which additionally includes a diluent.

Claim 9 claims a composition according to claim 8 wherein the diluent is microcrystalline cellulose.

Claim 10 claims a composition according to claim 1 which additionally includes a lubricant.

Claim 11 claims a composition according to claim 10 wherein the lubricant is magnesium stearate.


Examiner has not indicated why the prosecution of all claims in the application presents a serious burden for prosecution. Applicants believe that the subject matter of the galenic composition represented in all of the claimed species is searchable and presents no extraordinary effort for prosecution. In addition, the process claims (i.e. method claims 11-13) are dependent upon the use of the oral form claimed in claim 1. Applicants therefore respectfully request that the Examiner withdraw the present restriction requirement.

Alternatively, Applicants herein reserve their right to elect prosecution of the remaining species and claims for further prosecution in the future.

Applicants respectfully request entry of this amendment and favorable consideration of the claims in light thereof. No fee is believed due in this Application however the Examiner is authorized to charge any additional fees which may be due under 37 C.F.R. 1.17 or credit any overpayment to Account No. 19-0134 in the name of Novartis Corporation. If it will advance prosecution of this matter the Examiner is encouraged to contact the Applicants' undersigned counsel at the phone number listed below.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7960

  
E. Jay Wilusz  
Attorney for Applicants  
Reg. No. 52,370

Date: 25 July 2003